uniQure files for FDA and UK approval of first-ever gene therapy for Huntington's disease
uniQure has submitted a marketing application to the US Food and Drug Administration (FDA) for AMT-130 (ifezuntirgene inilparvovec), its one-time gene therapy for Huntington's disease — a fatal, inherited brain disorder that gradually destroys movement, thinking and behaviour and currently has no treatment that slows it down. The company filed in parallel with the UK's medicines regulator, the MHRA. If cleared, AMT-130 would be the first-ever treatment that targets the genetic cause of Huntington's rather than just its symptoms.
The therapy is delivered by surgically injecting it directly into a deep region of the brain, where it is designed to lower the amount of the harmful mutant huntingtin protein that drives the disease. uniQure is backing the filing with three-year data from an early-stage trial (announced in September 2025) that showed a 75% slowing of disease progression compared with an external group of untreated patients drawn from a natural-history database.
uniQure has asked the FDA for priority review; if granted, the agency could set a decision date for a potential accelerated approval around late April or early May 2027. The filing caps a turbulent regulatory saga: the FDA had reversed position on the data more than once during 2025 under its previous leadership before ultimately allowing the company to proceed.
Source: BioSpace, 2 September 2026.